UK MHRA forum homes in on uncertainties over software as devices
This article was originally published in RAJ Devices
Some three months after the amending medical devices legislation (Directive 2007/47/EC) came into effect in Europe, there is still a “significant lack of clarity” about what the new legislation “will really mean in practice” in relation to the oversight of software systems classified as devices1,2.
You may also be interested in...
As companies undergo pharmacovigilance inspections from a growing multitude of regulatory authorities from around the globe, a senior pharmaceutical industry executive discusses how her company has been handling this complex and challenging task.
While inspection interviews can be stressful for drug firms, a Dutch pharmacovigilance inspector reassures companies that any responses made during the process cannot undo any good work they have already done. And they can also correct any wrong answers later on.
The Saudi Food & Drug Authority looks at the number of individual case safety reports (ICSRs) submitted by a company, among other risk-based factors, when drawing up its list for routine pharmacovigilance inspections.